Clinical Trial Detail

NCT ID NCT03504397
Title A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer (Spotlight)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Astellas Pharma Global Development, Inc.
Indications

gastroesophageal junction adenocarcinoma

gastric adenocarcinoma

Therapies

Fluorouracil + Leucovorin + Oxaliplatin + Zolbetuximab

Fluorouracil + Leucovorin + Oxaliplatin

Age Groups: senior adult

Additional content available in CKB BOOST